The Impact of Phosphate Metabolism on Healthy Aging

Status Suspended

Clinical Trial Summary

Determine the association between duration and dose of chronic conventional therapy with Pi and renal (nephrocalcinosis/nephrolithiasis), vascular (endothelial function), and cardiovascular function (echo- cardiography) in patients with hereditary hypophosphatemic rickets with hypercalciuria (HHRH) and patients with X-linked hypophosphatemia (XLH).

Clinical Trial Description

The central hypothesis of this proposal is that patients with X-linked hypophosphatemia (XLH), when matched for duration and dose of phosphate (Pi) therapy to patients with hereditary hypophosphatemic rickets with hypercalciuria (HHRH), will evidence greater cardiovascular and vascular debility than patients with HHRH. The overall objectives of this project are to utilize our existing longitudinal databases for individuals with XLH and HHRH through an interdisciplinary collaboration between pediatric and adult endocrinology to: i) quantify the impact of exposure to Pi therapy across the lifespan on cardiovascular and renal complications, which are key aging endpoints, ii) determine the acute response to Pi loading in XLH and HHRH by studying the changes in surrogate markers of cardiovascular and renal function. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03771105
Study type	Interventional
Source	Yale University
Contact
Status	Suspended
Phase	Early Phase 1
Start date	January 1, 2019
Completion date	August 2024

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT04519762` - Levels of 'Hypophosphatemia Affect Outcome of Septic Patients in ICU	Phase 4
Enrolling by invitation	`NCT04502784` - Investigation of Hypophosphataemia Following Intravenous Iron
Completed	`NCT03529058` - Hypophosphatemia as a Predictive Marker of Mortality During Sepsis in ICU
Terminated	`NCT01011114` - Using Cinacalcet to Treat the Hypophosphatemia of Early Kidney Transplant	N/A
Completed	`NCT05098249` - Ferric Carboxymaltose With or Without Phosphate Substitution for the Treatment of Iron Deficiency or Iron Deficiency Anemia	Phase 4
Not yet recruiting	`NCT06350955` - IV Iron-induced Hypophosphatemia After RYGB	Phase 4
Completed	`NCT00688077` - FGF-23 Suppressibility by Calcitonin	N/A
Recruiting	`NCT04814641` - Hypophosphatemia and Bronchiolitis
Recruiting	`NCT01660308` - Observing the Changes of Fibroblast Growth Factor 23 in Patients of Tumor Induced Osteomalacia	N/A
Active, not recruiting	`NCT03976440` - Simplified Regional Citrate Anticoagulation Protocols for CVVH, CVVHDF and SLED: a Pilot Study
Recruiting	`NCT05909722` - Validation of the GIDS and Description of Phosphate Disorders
Completed	`NCT03581591` - Open Label Trial Assessing Safety and Efficacy of Burosumab (KRN23), in a Patient With ENS and Hypophosphatemic Rickets	Phase 3
Completed	`NCT03740802` - Hypophosphatemia as a Predictor in Surgical Resuscitation Sepsis
Active, not recruiting	`NCT06112236` - Effects of Treatments for Anemia and Iron Deficiency on the Electrolyte Balance in Lung Transplant Recipients: A Special Focus on Hypophosphatemia
Completed	`NCT03489993` - FGF23 and Angiotensin-(1-7) in Hypophosphatemia (GAP)
Completed	`NCT00975000` - Treatment of Autonomous Hyperparathyroidism in Post Renal Transplant Recipients	Phase 3
Withdrawn	`NCT02837523` - Biomarker for Cystinosis Disease: BioCystinosis (BioCystinosis)
Not yet recruiting	`NCT06344546` - Metabolic Pathway Analysis in Intensive Care Unit Patients With Refeeding Syndrome